MYOV News and Press, Myovant Sciences Ltd. From 10/26/22

Myovant Sciences press release ( NYSE: MYOV ): Q2 GAAP EPS of -$0.47 beats by $0.02 . Revenue of $104.8M (+34.5% Y/Y) beats by $11.33M . Cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement totaled $412.6...

On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstand...

Summary The backbone of the company is Relugolix, a product in a platform already approved in three indications and planned to be investigated in additional indications. Relugolix has the potential to become the new standard of care in each indication and to generate billions in s...

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Easter...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sundry Photography / Shutterstock.com Beyond Meat (NASDAQ: BYND ) stock is on the move Monday after the company revealed Beyond Steak , a new plant-based steak product. The new product from the compan...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today’s market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don’t already own. Further...

Japan's Sumitovant Biopharma is acquiring the remaining 48% stake in Myovant Sciences ( NYSE: MYOV ) for $1.7B, which it currently does not own to take the London-based women's health company private. Sumitovant, a unit of Sumitomo Pharma ( OTCPK:DNPUF ...

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address U...

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today by Myovant Sciences, Inc. (NYSE: MYOV), please note that the date of the conferenc...

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call wi...